{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:58:09Z","timestamp":1765961889789,"version":"3.45.0"},"reference-count":26,"publisher":"Tech Science Press","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.055100","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T03:59:16Z","timestamp":1741579156000},"page":"1283-1288","source":"Crossref","is-referenced-by-count":2,"title":["Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies"],"prefix":"10.32604","volume":"33","author":[{"given":"GIOVANA GOMES","family":"CHAGAS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RUAN","family":"PIMENTA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NAYARA IZABEL","family":"VIANA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1586\/14737159.2015.1013032","article-title":"The current state of molecular cytogenetics in cancer diagnosis","volume":"15","author":"Liehr","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref3","first-page":"731","article-title":"Leukemia: an overview for primary care","volume":"89","author":"Davis","year":"2014","journal-title":"Am Fam Physician"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e1509","DOI":"10.1002\/wsbm.1509","article-title":"Genome wide association studies for treatment-related adverse effects of pediatric acute lymphoblastic leukemia","volume":"13","author":"Franca","year":"2021","journal-title":"WIREs Mech Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"a035220","DOI":"10.1101\/cshperspect.a035220","article-title":"Chronic lymphocytic leukemia","volume":"11","author":"Chiorazzi","year":"2021","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref6","first-page":"e61983","article-title":"A comprehensive review of monoclonal antibodies in modern medicine","volume":"16","author":"Kothari","year":"2024","journal-title":"Tracing Evol Revolutionary Ther Approach. Cureus"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/imr.13387","article-title":"The function of antibodies","volume":"328","author":"Da\u00ebron","year":"2024","journal-title":"Immunol Rev"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1182\/bloodadvances.2022009594","article-title":"A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial","volume":"7","author":"Michallet","year":"2023","journal-title":"Blood Adv"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2016004176","article-title":"Microenvironmental agonists generate","volume":"1","author":"Jayappa","year":"2017","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bcp.14962","article-title":"Proapoptotic and immunomodulatory effects of SYK inhibitor entospletinib in combination with obinutuzumab in patients with chronic lymphocytic leukaemia","volume":"88","author":"Lam","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1007\/s12325-022-02170-w","article-title":"Pharmacokinetics and exposure-response analysis of venetoclax + obinutuzumab in chronic lymphocytic leukemia: phase 1b study and phase 3 CLL14 trial","volume":"39","author":"Samineni","year":"2022","journal-title":"Adv Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S2352-3026(22)00038-2","article-title":"Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial","volume":"9","author":"Marks","year":"2022","journal-title":"Lancet Haematol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.ctrv.2015.10.008","article-title":"The use of combinations of monoclonal antibodies in clinical oncology","volume":"41","author":"Henricks","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3904\/kjim.2022.401","article-title":"Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study","volume":"38","author":"Baek","year":"2023","journal-title":"Korean J Intern Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1182\/bloodadvances.2022009382","article-title":"Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia","volume":"7","author":"Wallace","year":"2023","journal-title":"Blood Adv"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41375-022-01576-3","article-title":"Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial","volume":"36","author":"Pennesi","year":"2022","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.35505","article-title":"Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: development, current status, and future directions","volume":"130","author":"Kantarjian","year":"2024","journal-title":"Cancer"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e836","DOI":"10.1016\/j.clml.2022.04.022","article-title":"Time to first subsequent salvage therapy in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"22","author":"Stelljes","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/j.clml.2024.06.002","article-title":"Efficacy of chemotherapy-free regimens in the treatment of philadelphia chromosome-positive acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"24","author":"Ali","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.3324\/haematol.2022.282116","article-title":"High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518\u2014VERITAS study","volume":"108","author":"Mauro","year":"2023","journal-title":"Haematologica"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2021013208","article-title":"Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia","volume":"139","author":"Huber","year":"2022","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/jamaoncol.2018.1915","article-title":"Progress and innovations in the management of adult acute lymphoblastic leukemia","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-6\/OncolRes-33-06-55100\/OncolRes-33-55100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T01:32:30Z","timestamp":1763343150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n6\/61330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.055100","relation":{},"ISSN":["1555-3906"],"issn-type":[{"type":"electronic","value":"1555-3906"}],"subject":[],"published":{"date-parts":[[2025]]}}}